Related Experiment Video
Updated: Jul 26, 2026
Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis
Published on: December 8, 2011
In Vivo Efficacy of Lacticaseibacillus rhamnosus L8020 in a Mouse Model of Oral Candidiasis
Rei Ito1, Yuichi Mine2, Yoshie Yumisashi1
1Department of Oral Biology & Engineering, Division of Oral Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Abstract:
Oral candidiasis presents with multiple clinical manifestations. Among known pathogenic Candida species, Candida albicans is the most virulent and acts as the main causative fungus of oral candidiasis. Novel treatment modalities are needed because of emergent drug resistance and frequent candidiasis recurrence. Here, we evaluated the ability of Lacticaseibacillus rhamnosus L8020, isolated from healthy and caries-free volunteers, to prevent against the onset of oral candidiasis in a mouse model. Mice were infected with C. albicans, in the presence or absence of L. rhamnosus L8020. The mice were treated with antibiotics and corticosteroid to disrupt the oral microbiota and induce immunosuppression. We demonstrated that oral consumption of L. rhamnosus L8020 by C. albicans-infected mice abolished the pseudomembranous region of the mouse tongue; it also suppressed changes in the expression levels of pattern recognition receptor and chemokine genes. Our results suggest that L. rhamnosus L8020 has protective or therapeutic potential against oral candidiasis, which supports the potential use of this probiotic strain for oral health management.
Insights
Lacticaseibacillus rhamnosus L8020, a probiotic, shows promise in preventing and treating oral candidiasis. This study found it reduced fungal load and suppressed inflammatory gene expression in a mouse model.
Area of Science:
- Microbiology
- Immunology
- Oral Health
Background:
- Oral candidiasis is a fungal infection caused by Candida species, primarily Candida albicans.
- Emerging drug resistance and recurrent infections necessitate novel therapeutic strategies.
- Probiotics offer a potential avenue for managing oral infections and promoting oral health.
Purpose of the Study:
- To evaluate the efficacy of Lacticaseibacillus rhamnosus L8020 in preventing oral candidiasis.
- To investigate the impact of L. rhamnosus L8020 on Candida albicans infection in an immunosuppressed mouse model.
Main Methods:
- A mouse model of oral candidiasis was established using Candida albicans infection.
- Mice were treated with antibiotics and corticosteroids to induce immunosuppression and disrupt oral microbiota.
- Lacticaseibacillus rhamnosus L8020 was administered orally to assess its protective effects.
Main Results:
- Oral administration of L. rhamnosus L8020 significantly reduced the pseudomembranous lesions on the tongue in infected mice.
- L. rhamnosus L8020 suppressed the altered expression of pattern recognition receptor and chemokine genes associated with infection.
- The probiotic strain demonstrated a protective effect against Candida albicans-induced oral candidiasis.
Conclusions:
- Lacticaseibacillus rhamnosus L8020 exhibits potential as a therapeutic agent for oral candidiasis.
- This probiotic strain may be beneficial for oral health management, particularly in preventing or treating Candida infections.
